EGFR and prostate carcinoma: Dysregulation of MYC proto‐oncogene, bHLH transcription factor (MYC) [13, 19], mammalian target of rapamycin complex 1 (mTORC1) [13], mitogen‐activated protein kinase (MAPK) [13], Janus kinase ‐ signal transducer and activator of transcription (JAK‐STAT) [13], and epidermal growth factor receptor (EGFR) [21] expression and/or pathways has also been shown to be enriched in cribriform prostate cancer.